丹参酮Ⅱ-A磺酸钠联合低分子肝素治疗原发性肾病综合征的疗效观察  

Curative Effect of Sulfotanshinone United with Low Molecular Heparin in Primary Nephrosis Synthesis

作　　者：蔡佳盈[1] 吴建平[1] 沈世忠[1] 孙凌云[1] 

机构地区：[1]福建医科大学附属泉州第一医院肾内科,福建泉州362000

出　　处：《河北医学》2009年第10期1144-1146,共3页Hebei Medicine

摘　　要：目的:观察常规治疗基础上丹参酮Ⅱ-A磺酸钠联合低分子肝素对原发性肾病综合征(PNS)的治疗效果及安全性。方法:将45例原发性肾病综合征患者随机分为两组,分别为常规治疗组(对照组)22例及丹参酮Ⅱ-A磺酸钠联合低分子肝素治疗组(治疗组)23例。对照组给予激素、潘生丁、利尿剂等药物治疗,治疗组在此基础上加用丹参酮Ⅱ-A磺酸钠及低分子肝素。结果:经2周治疗后,治疗组甘油三脂、胆固醇、24h尿蛋白定量、血肌酐均明显下降(P<0.05),血浆蛋白明显上升(P<0.05)。结论:在常规治疗基础上丹参酮Ⅱ-A磺酸钠联合低分子肝素治疗PNS是一种有效安全的方法。Objective： To discuss in conventional treatment foundation sulfotanshinone unites low molecular heparin to the primary nephrosis synthesis. Method： 45 eases of primary nephrosis synthesis patients were divided into two groups respectively（ control group） 22 examples, Sulfotanshinone unites the low molecular heparin treatment group be the conventional treatment group （ treatment group ） 23 examples, the control group gave the hormone, and Pan Shengding, diuretics, the treatment group added in this foundation with Sulfotanshinone and the low molecular heparin. Result： Treatment group and the control group were treated for 14 days ,its glycerin（ TG） ,cholesterol（TC） ,24 hour urine protein eet decreased obviously（ P 〈0.05 ）, protein substitute for plasma increased obvious （ P 〈 0.05 ）. Conclusion ： Sulfotanshinone unites the low molecular heparin in the conventional treatment foundation to treat PNS might be one effective and safety method.

关 键 词：丹参酮Ⅱ-A磺酸钠 低分子肝素 原发性肾病综合征 

分 类 号：R692.3[医药卫生—泌尿科学]